Clinical Trial: Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis

Brief Summary: Takayasu's arteritis(TAK) is a rare systemic vasculitis which can cause ischemia or inflammation of the involved organs and increase the overall mortality rate.The traditional treatment of TAK is primarily empirical. The most commonly used drugs for treating active TAK are glucocorticosteroids(GC) and immunosuppressants. However, the genital toxicity of CYC has limited its long term use. In a pilot study carried out by the principal investigator of this study has shown that mycophenolate mofetil(MMF) combined with MTX is effective and with few adverse effects. The purpose of this prospective open-label study is to compare the efficacy and safety of GC+MMF+MTX with GC+CYC followed by GC+AZA for the treatment of active TAK. 150 patients with active TAK will be recruited and randomized in a 2:1 ratio to GC+MMF+MTX group and C+CYC and AZA group. Patients were followed for 52 weeks for efficacy and safety assessment.

Detailed Summary: Takayasu's arteritis(TAK) is a rare systemic vasculitis which mainly involves aorta and its major branches. However,it is more prevalent in countries and areas along the silk road.Young women at child-bearing age is the most prevalent population.It can cause ischemia or inflammation of the involved organs and increase the overall mortality rate.Although it may be lethal in some patients,it is not well studied due to the rareness of the disease.The traditional treatment of TAK is primarily empirical. The most commonly used drugs for treating active TAK are glucocorticosteroids(GC) and immunosuppressants including cyclophosphamide(CYC), methotrexate(MTX) and azathioprine(AZA) etc. However,no of these drugs have been well studied. In addition, the genital toxicity of CYC, the first line medication for active TAK, has become the major limitation for its long term use for a chronic disease like TAK. Therefore, new immunosuppressants with less toxicity,especially with much less genital toxicity and low malignancy risk is essentially necessary. In a pilot study carried out by the principal investigator of this study has shown that mycophenolate mofetil(MMF) combined with MTX is effective and with few adverse effects. The purpose of this prospective open-label study is to compare the efficacy and safety of GC+MMF+MTX with GC+CYC followed by GC+AZA for the treatment of active TAK. 150 patients with active TAK will be recruited and randomized in a 2:1 ratio to GC+MMF+MTX group and C+CYC and AZA group. Patients were followed for 52 weeks to assess the efficacy and safety.
Sponsor: Chinese SLE Treatment And Research Group

Current Primary Outcome: Proportion of patients with complete remission [ Time Frame: 52 weeks ]

The proportion of patients who reached the pre-defined criteria of complete remission in both groups


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Proportion of patients with partial remission [ Time Frame: 52 weeks ]
    Proportion of patients who reached the pre-defined partial remission criteria of the disease
  • Safety profile of MMF combined with MTX [ Time Frame: 52 weeks ]
    Proportion of adverse events in both treatment groups
  • Rate of complications [ Time Frame: 52 weeks ]
    Proportion of patients with complications in both treatment group


Original Secondary Outcome: Same as current

Information By: Chinese SLE Treatment And Research Group

Dates:
Date Received: March 13, 2017
Date Started: March 16, 2017
Date Completion: December 1, 2018
Last Updated: April 4, 2017
Last Verified: April 2017